Brainstorm Cell Therapeutics Inc (OQ:BCLI)

Business Focus: Biotechnology & Medical Research

Apr 16, 2024 06:30 pm ET
Apr 11, 2024 06:00 am ET
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
NEW YORK, April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (the "Rule").
Apr 10, 2024 06:00 am ET
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo.Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS.
Apr 09, 2024 06:00 am ET
Apr 08, 2024 06:00 am ET
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time
Apr 01, 2024 08:05 am ET
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
Conference call planned for early April 2024 to provide update on NurOwn program
Feb 27, 2024 05:30 am ET
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients
Feb 23, 2024 05:00 am ET
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS).
Feb 13, 2024 05:30 am ET
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
NEW YORK, Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland.
Jan 02, 2024 11:57 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Jan 02, 2024 10:45 am ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 02, 2024 10:00 am ET
BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or “the Company”) (NASDAQ: BCLI)...
Jan 02, 2024 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Jan 01, 2024 01:55 pm ET
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 31, 2023 08:08 am ET
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm.
Dec 29, 2023 09:00 pm ET
BRAINSTORM CELL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact t
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in t
Dec 28, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brainstorm Cell, SolarEdge, and Barclays and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), SolarEdge Technologies, Inc....
Dec 28, 2023 06:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
NEW YORK, Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Dec 28, 2023 05:03 pm ET
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 28, 2023 01:07 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Dec 28, 2023 11:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Dec 28, 2023 08:00 am ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Dec 27, 2023 02:48 pm ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
LOS ANGELES, Dec. 27, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Dec 27, 2023 10:00 am ET
BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or “the Company”) (NASDAQ: BCLI)...
Dec 27, 2023 09:30 am ET
BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Dis
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Dec 27, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Dec 26, 2023 11:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 26, 2023 12:07 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 26, 2023 09:00 am ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 26, 2023 06:30 am ET
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes.
Dec 26, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Dec 25, 2023 05:10 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 24, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Dec 22, 2023 11:11 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Dec 21, 2023 11:45 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 21, 2023 01:21 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. (BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Dec 21, 2023 12:14 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Dec 21, 2023 08:00 am ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Dec 20, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Dec 20, 2023 12:31 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Dec 20, 2023 10:00 am ET
BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or “the Company”) (NASDAQ: BCLI)...
Dec 20, 2023 10:00 am ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Dec. 20, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Dec 20, 2023 08:00 am ET
BrainStorm Issues 2023 Letter to Shareholders
NEW YORK, Dec. 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.
Dec 19, 2023 01:44 pm ET
ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 19, 2023 12:19 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 19, 2023 09:30 am ET
BRAINSTORM ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Dec 19, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Dec 18, 2023 01:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Dec 18, 2023 11:00 am ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 18, 2023 07:46 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. (BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Dec 18, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Dec 15, 2023 09:34 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 15, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Dec 15, 2023 05:36 pm ET
Robbins LLP Reminds Brainstorm Cell Therapeutics Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Against BCLI
Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September...
Dec 15, 2023 11:00 am ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
LOS ANGELES, Dec. 15, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Dec 15, 2023 09:30 am ET
BRAINSTORM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Direct
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Dec 14, 2023 01:13 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Dec 14, 2023 12:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
Dec 14, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Dec 13, 2023 04:10 pm ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
LOS ANGELES, Dec. 13, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Dec 13, 2023 12:37 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
, December 13, 2023 – Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...
Dec 12, 2023 12:07 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 12, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Dec 11, 2023 07:45 pm ET
ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 11, 2023 01:20 pm ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 11, 2023 01:02 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Dec 11, 2023 06:30 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 10, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Dec 10, 2023 07:30 am ET
BRAINSTORM DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Dec 10, 2023 07:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
NEW YORK, Dec. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 07, 2023 11:05 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Dec 07, 2023 09:15 am ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Dire
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Dec 07, 2023 07:40 am ET
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
Meeting Provided a Clear Path for Planned Phase 3b Trial
Dec 06, 2023 11:00 am ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Dec. 6, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Dec 06, 2023 08:31 am ET
Thinking about buying stock in Brainstorm Cell Therapeutics, Clearmind Medicine, Phio Pharmaceuticals, Aspen Aerogels, or Immunoprecise Antibodies?
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCLI, CMND, PHIO, ASPN, and IPA.
Dec 05, 2023 07:38 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Dec 05, 2023 12:08 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 05, 2023 07:30 am ET
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Th
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Dec 05, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Dec 04, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Dec 04, 2023 01:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529,...
Dec 04, 2023 01:05 pm ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 04, 2023 07:00 am ET
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 04, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Dec. 4, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Dec 03, 2023 06:40 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 02, 2023 09:15 am ET
BRAINSTORM SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Disc
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Dec 01, 2023 02:58 pm ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
LOS ANGELES, Dec. 1, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Nov 30, 2023 04:23 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Nov 30, 2023 01:07 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Nov 30, 2023 12:07 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 30, 2023 07:30 am ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 29, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Nov 29, 2023 01:20 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. (BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Nov 29, 2023 10:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Nov 28, 2023 04:43 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
NEW YORK, Nov. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 28, 2023 10:00 am ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
LOS ANGELES , Nov. 28, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Nov 28, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Nov. 28, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Nov 27, 2023 01:11 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Nov 27, 2023 12:00 pm ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 27, 2023 04:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK, Nov. 27, 2023 /PRNewswire/ --Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders:
Nov 26, 2023 09:36 pm ET
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Nov 26, 2023 09:15 am ET
BRAINSTORM ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Opt
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may...
Nov 25, 2023 07:30 am ET
BRAINSTORM DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 24, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Nov 22, 2023 12:22 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Nov 22, 2023 07:00 am ET
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 21, 2023 04:39 pm ET
Brainstorm Cell Therapeutics Inc. Class Action Reminder: Contact Robbins LLP for Information About the BCLI Class Action
Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September...
Nov 21, 2023 03:10 pm ET
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Nov. 21, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
Nov 21, 2023 01:38 pm ET
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Nov 21, 2023 01:07 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 15, 2022 and...
Nov 21, 2023 12:07 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 21, 2023 10:07 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Nov 21, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Nov. 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Nov 20, 2023 01:46 pm ET
BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or “the Company”) (NASDAQ: BCLI) and certain of its officers.
Nov 20, 2023 12:59 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. (BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Nov 20, 2023 07:10 am ET
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
Meeting will take place on December 6; Company plans to seek Special Protocol Assessment (SPA)
Nov 20, 2023 04:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders:
Nov 19, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Nov 19, 2023 10:00 am ET
BRAINSTORM ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Opt
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Nov 18, 2023 07:30 am ET
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 17, 2023 03:30 pm ET
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Nov 17, 2023 11:00 am ET
DEADLINE ALERT for DCGO, SEDG, BCLI, BCS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 17, 2023 06:00 am ET
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes
Nov 16, 2023 04:38 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc....
Nov 16, 2023 01:11 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Nov 16, 2023 12:06 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 16, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Nov. 16, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Nov 15, 2023 12:36 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Nov 14, 2023 04:03 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Nov 14, 2023 02:27 pm ET
BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or “the Company”) (NASDAQ: BCLI) and certain of its officers.
Nov 14, 2023 12:53 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 15, 2022 and...
Nov 14, 2023 09:45 am ET
BRAINSTORM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Thei
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Nov 14, 2023 06:05 am ET
Nov 14, 2023 04:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Nov 13, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Nov 13, 2023 07:30 pm ET
Brainstorm Cell Therapeutics Inc. (BCLI) Investors: Shareholders with Large Losses Should Contact Robbins LLP Regarding the BCLI Class Action
Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023. Brainstorm Cell is a biotechnology company that develops and comme
Nov 13, 2023 03:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Nov 13, 2023 01:12 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc.. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Nov 13, 2023 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
Law Offices of Howard G. Smith reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023, inclusive (the
Nov 13, 2023 07:00 am ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 13, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 13, 2023 04:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders:
Nov 11, 2023 08:48 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the...
Nov 11, 2023 10:12 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
NEW YORK, Nov. 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 10, 2023 12:07 pm ET
DEADLINE ALERT for SEDG, BCLI, BCLYF/BCS, and OTLK: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Nov 09, 2023 05:30 pm ET
BRAINSTORM INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Th
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Nov 09, 2023 12:44 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Nov 09, 2023 04:45 am ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Nov. 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit.
Nov 08, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the...
Nov 08, 2023 03:32 pm ET
Brainstorm Cell Therapeutics Inc. (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Brainstorm Cell Therapeutics Inc.
Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September...
Nov 08, 2023 03:14 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Nov 08, 2023 12:30 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 – (NASDAQ: BCLI)
The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc. Shareholders who purchased shares of BCLI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
Nov 08, 2023 07:00 am ET
BRAINSTORM SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 07, 2023 03:44 pm ET
Class Action Lawsuit Filed Against Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors – Nationally Ranked Investors’ Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant
Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI). The lawsuit alleges Brainstorm Cell made false or...
Nov 07, 2023 03:34 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between August 15, 2022 and...
Nov 07, 2023 12:57 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
NEW YORK, Nov. 7, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Brainstorm Cell Therapeutics Inc..
Nov 07, 2023 12:06 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Nov 07, 2023 11:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023, inclusive (the “Class Period”). Brainstorm Cell investors have until Janua
Nov 07, 2023 05:00 am ET
BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update
NEW YORK, Nov. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call on Tuesday, November 14th at 8:30 a.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2023 and provide a corporate update.
Nov 06, 2023 11:45 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 06, 2023 08:23 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023,...
Nov 06, 2023 06:17 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Nov 06, 2023 02:10 pm ET
Brainstorm Cell Therapeutics Inc. (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Brainstorm Cell Therapeutics Inc.
Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023. Brainstorm Cell is a biotechnology company that develops and comme
Nov 06, 2023 02:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Nov 06, 2023 12:51 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) investors concerning the Company’s possible violations of federal securities laws.
Nov 06, 2023 12:30 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. (BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm...
Nov 06, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 06, 2023 04:45 am ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Brainstorm Cell Investors of a Lead Plaintiff Deadline of January 2, 2024
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Attention Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell") (NASDAQ: BCLI) shareholders:
Nov 04, 2023 09:00 am ET
BRAINSTORM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Barclays To Contact Him Directly To Discuss Their
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Brainstorm Cell Therapeutics Inc. (“Brainstorm” or the “Company”) (NASDAQ: BCLI) and reminds investors of the January 2, 2024 deadline to seek...
Nov 03, 2023 09:00 pm ET
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Brainstorm Cell securities between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). Investors have until January 2, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsu
Nov 03, 2023 07:57 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ:
Nov 03, 2023 03:59 pm ET
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Brainstorm Cell Therapeutics Inc. (BCS)
Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) securities between August 15, 2022 and September...
Nov 03, 2023 08:00 am ET
BRAINSTORM SHAREHOLDER ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Brainstorm between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
Nov 03, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 02, 2023 04:55 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. (BCLI)
Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Brainstorm...
Nov 02, 2023 07:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 01, 2023 09:45 pm ET
BCLI EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated
WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023,...
Nov 01, 2023 06:02 pm ET
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. – BCLI
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Brainstorm Cell investors under the federal securities laws.
Oct 30, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 24, 2023 07:00 am ET
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn® for the Treatment of ALS
-  Resource consumption will be reduced by 50% to accelerate ALS development
Oct 19, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 18, 2023 06:00 am ET
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
-  Path forward for ALS is a registrational Phase 3b U.S. clinical trial -
Oct 16, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 16, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 11, 2023 10:15 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 10, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 10, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 08, 2023 11:15 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 07, 2023 07:30 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 06, 2023 05:11 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation – BCLI
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) resulting from allegations that Brainstorm Cell may have...
Oct 06, 2023 09:31 am ET
Thinking about buying stock in Mama's Creations, Brainstorm Cell Therapeutics, Meiwu Technology, Maia Biotechnology, or Hanryu Holdings?
NEW YORK, Oct. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MAMA, BCLI, WNW, MAIA, and HRYU.
Oct 05, 2023 11:55 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.
Oct 05, 2023 04:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of the securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.